News & Blogs

House Energy & Commerce Committee: Rep. Harshbarger Questions AARP–UnitedHealth Financial Ties

“Mr. Hemsley, you know I’m used to following the money, especially when patients are told something is about affordability, and AARP presents itself as an independent non-profit speaking for seniors. But its own financial filings show that UnitedHealth paid AARP over nine billion dollars in a single deal—far more than the AARP brings in from membership dues, and more than four times its annual operating revenue. They also earn royalties tied directly to insurance premiums,…

Learn More

For Big Insurers, Tomorrow’s Congressional Hearings Is the Super Bowl

If I were still in my role as a Cigna executive, one of my responsibilities would be to prepare CEO David Cordani for his first ever appearance before a Congressional committee tomorrow. When I was the VP of corporate communications, I wrote speeches for the CEO and staffed him for any public-facing appearances. I was also the gatekeeper. Reporters had to go through me to interview anyone at Cigna, and I would rarely allow a reporter…

Learn More

UnitedHealth Used Aggressive Tactics to Boost Medicare Payments, Senate Report Finds

UnitedHealth Group deployed aggressive tactics to collect payment-boosting diagnoses for its Medicare Advantage members, a Senate committee investigating the company’s practices said. In Medicare Advantage, the federal government pays insurers a lump sum to oversee medical benefits for seniors and disabled people. The government pays extra for patients with certain costly medical conditions, a process called risk adjustment. The new report, based on a review of 50,000 pages of records UnitedHealth turned over to the Senate…

Learn More

Commitment to Seniors Opposes New “Most Favored Nation” Drug Pricing Models

Washington, D.C. — December 23, 2025 — Commitment to Seniors, a project of American Commitment, opposes the Trump administration’s new drug pricing models—Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicine Against Rising Drug Costs (GUARD)—which import Most Favored Nation (MFN) drug price controls directly into Medicare Part B and Part D. These price controls will negatively impact America’s prescription drug market, which seniors heavily rely on. By tying U.S. reimbursement rates to those set in other…

Learn More

Fox News Live: Phil Kerpen on Price Controls

This is a really tough problem for the simple reason that if another country is getting a free ride, it’s very hard to convince them to end it. For a long time, people in the US, especially people left of center, just said let’s pay European prices. Instead of the rest of the world getting a free ride, there’s nothing to ride on. There’s no incentive for investment for developing new cures and new treatments…

Learn More

Drugmakers Are Ditching Middlemen to Sell Directly to Patients

Drugmakers are moving to sell their medicines directly to patients, abandoning the middlemen they have long relied on. The shift is a huge departure from how pharmaceutical companies including Eli Lilly, Novo Nordisk and Pfizer have sold drugs for decades and threatens the multibillion-dollar business of firms that have traditionally filled prescriptions. It is saving some patients hundreds of dollars off the cost of prescriptions because companies have been lowering the prices for drugs sold directly.

Learn More

Trump Strikes a Good Drug Deal

President Trump struck a deal on Monday with the U.K.’s Labour government that will raise drug prices on the other side of the pond in return for a tariff reprieve. At last a good drug deal: Both sides can claim a victory while mitigating self-inflicted damage to their countries. The President has long complained, with some justification, that other developed countries free-ride on U.S. innovation and consumers by requiring manufacturers to sell drugs to government-run…

Learn More

Biden’s IRA Is Harming Cancer Patients

Democrats’ 2022 Inflation Reduction Act wasn’t designed to kill cancer innovation, but new evidence reveals that’s what it’s doing. The law strongly discourages drug companies from performing the “follow-on” research after initial discoveries that accounts for a disproportionate share of progress in the fight against cancer. The crux of the problem is that the IRA imposes price caps that shorten the effective life of a patent and applies those price controls even to later-approved uses.…

Learn More